Immunic Therapeutics

NEWS

Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.

Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management

While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.

October 6, 2025

5 min read

Ben Hargreaves

IN THE PRESS

Press Releases

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

November 27, 2025

4 min read

Press Releases

Immunic to Participate in Industry and Investor Conferences in November 2025

October 29, 2025

4 min read

Press Releases

Immunic to Participate in Scientific and Investor Conferences in October 2025

October 1, 2025

7 min read

Press Releases

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

September 25, 2025

15 min read

Press Releases

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium’s Dose Strengths in Progressive Multiple Sclerosis

September 9, 2025

8 min read

Press Releases

Immunic to Participate in Investor and Scientific Conferences in September 2025

September 4, 2025

7 min read

Press Releases

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

June 24, 2025

9 min read

Press Releases

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

June 5, 2025

11 min read

Press Releases

Immunic to Participate in Investor, Scientific and Industry Conferences in June 2025

June 2, 2025

6 min read

Press Releases

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025

7 min read

JOBS